[Topical Mitomycin C as a therapy of conjunctival tumours].
Surgical excision with tumour free margins is the gold standard for squamous cell and melanocytic tumours of the conjunctiva. In cases of diffuse and extensive tumours a complete surgical excision is sometimes not possible. Therefore, alternative or adjuvant therapies are required. Topical chemotherapy with mitomycin C (MMC) is increasingly finding use in clinical practice. MMC has several advantages such as good tolerability and mild side effects. Present studies have shown that mitomycin C is a good option in squamous cell neoplasia of the conjunctiva. However, further multi-centre studies and long-term follow-up are needed.The results in treating melanocytic tumours of the conjunctiva with MMC are less convincing. MMC seems to be an option for the treatment of primary acquired melanosis (PAM); but, if the tumour is suspicious for melanoma primary chemotherapy with MMC is obsolete. In these cases MMC can only be used as an adjuvant therapy, otherwise tumour control is not assured. However, prospective randomized controlled trials are necessary for a final evaluation of MMC therapy in melanocytic tumours of the conjunctiva.
Schallenberg
M
M
Zentrum für Augenheilkunde, Abteilung für Erkrankungen des vorderen Augenabschnittes, Universität Duisburg-Essen, 45122, Essen, Deutschland. maurice.schallenberg@uk-essen.de
Niederdräing
N
N
Steuhl
K-P
KP
Meller
D
D
D000287:Administration, Topical; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D003230:Conjunctival Neoplasms / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000209:etiology; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D008548:Melanosis / Q000188:drug therapy; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin